Clinical trials: PARKINSON DISEASE (Disorder)
Parkinson's Disease
Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of KW-6500 when administered as long-term subcutaneous self-injections in Parkinson's disease patients with motor response complications on levodopa therapy.
- Trial name
- NCT00955318
- Testing
- KW-6500
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Depressive Symptoms, Parkinson's Disease
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total…
- Trial name
- ACCORDO (NCT01055379)
- Testing
- Rasagiline
- Where
- 12 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Lundbeck Italia S.p.A.
Parkinson's Disease
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
The purpose of this study is to determine the safety and efficacy of AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain.
- Trial name
- NCT00643890
- Testing
- Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Neurologix, Inc.
Parkinson's Disease
Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease
The purpose of this study is to assess the cognitive performance in patients with advanced Parkinson's disease receiving Deep Brain Stimulation (DBS) with settings predetermined clinically to settings derived from a…
- Trial name
- SAGE (NCT01230151)
- Testing
- GUIDE software, Version 0.1, Clinically defined stimulation parameters
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Intelect Medical, Inc.
Motor OFF Episodes Associated With Parkinson's Disease
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with Parkinson's Disease…
- Trial name
- NCT03391882
- Testing
- APL-130277, subcutaneous apomorphine
- Where
- 31 sites in Austria, France and 4 more
- Volunteers
- 113 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson Disease, Tremor
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual…
- Trial name
- NCT05642442
- Testing
- Suvecaltamide
- Where
- 37 sites in United States, Germany and 2 more
- Volunteers
- 169 people
- Sponsor
- Jazz Pharmaceuticals
Parkinson's Disease
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study
To evaluate DBS device settings and match with the features of the DBS care management software.
- Trial name
- DBS (NCT01750242)
- Testing
- Medtronic DBS system
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- MedtronicNeuro
PD
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
The purpose of the study is to evaluate the safety and tolerability of BBM-P002 for stereotactic injection to treat participants with idiopathic Parkinson's Disease (PD) during the dose-limiting toxicity (DLT) observation period.
- Trial name
- NCT07195825
- Testing
- Injecting BBM-P002 into the bilateral putamen
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Xinzhi BioMed Co., Ltd.
Advanced Idiopathic Parkinson's Disease
Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life…
- Trial name
- DAPHNE (NCT00141518)
- Testing
- Levodopa-carbidopa intestinal gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, percutaneous endoscopic gastrostomy tube (PEG tube)
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease
Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan
The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease
- Trial name
- NCT00212693
- Testing
- ONO-2506PO
- Volunteers
- 165 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Parkinson Disease
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa…
- Trial name
- ADOPTION (NCT04990284)
- Testing
- Opicapone, L-DOPA/DDCI
- Where
- 25 sites in Germany, Italy and 3 more
- Volunteers
- 106 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.
- Trial name
- NCT07522606
- Testing
- BIA 28-6156
- Where
- 36 sites in United States, Italy and 3 more
- Sponsor
- Bial R&D Investments, S.A.
Neoplasms
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumors for which there is no available…
- Trial name
- NCT02720068
- Testing
- Favezelimab, Pembrolizumab, Oxaliplatin
- Volunteers
- 481 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD.
- Trial name
- NCT00228150
- Testing
- SR57667B
- Where
- 13 sites in Austria, Canada and 11 more
- Volunteers
- 564 people
- Sponsor
- Sanofi
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts.
- Trial name
- NCT06483334
- Testing
- Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)
The purpose of the study is to investigate the incidences of psychiatric symptoms (example, hallucinations), somnolence and sudden onset of sleep, dyskinesia, and retinal degeneration-related events during treatment with Equfina…
- Trial name
- NCT04724109
- Testing
- Equfina
- Where
- 2 sites in Japan
- Volunteers
- 1,088 people
- Sponsor
- Eisai Co., Ltd.
Parkinson's Disease (PD)
Observational Study Evaluating Robotic Spinal Mobilization in 16 Parkinson's Disease Participants. The Study Recorded Changes in Mobility, Sit-to-stand Performance, and Pain Scores After a 2-week Intervention With the BackHug Device.
The goal of this completed observational pilot study was to evaluate the immediate and short-term clinical effects of robotic spinal mobilization on motor and non-motor symptoms in community-dwelling adults with Parkinson's…
- Trial name
- NCT07384364
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Pacla Medical Limited
Parkinson Disease
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
- Trial name
- NCT06809400
- Testing
- LY4006896
- Where
- 14 sites in United States, Japan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Parkinson's Disease, Tolerability
Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients
The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.
- Trial name
- NCT01023282
- Testing
- ACR325
- Where
- 2 sites in Germany
- Volunteers
- 22 people
- Sponsor
- NeuroSearch A/S
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.